GlassScriptPhysician profile
Tammy L Brown
NPI 1609845882
$2,125.50
in general payments reported to CMS, 2019-2025
32 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $119 · 2021: $427 · 2022: $419 · 2023: $344 · 2024: $316 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $454.04 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $173.05 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $170.59 | 2019-2025 | Breztri, Farxiga, Flumist Quadrivalent |
| Glaxosmithkline, LLC. | $142.40 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $120.03 | 2019-2023 | Rybelsus, Ozempic |
| Dexcom, INC. | $98.46 | 2022-2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $94.14 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $73.48 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $70.41 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.68 | 2019-2023 | Xifaxan |
| Allergan, INC. | $63.51 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.48 | 2020-2024 | Jardiance |
| Amgen INC. | $44.75 | 2022-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $42.64 | 2022 | |
| Genentech USA, INC. | $41.52 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $40.40 | 2019-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Vanda Pharmaceuticals INC. | $39.87 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $39.01 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $30.80 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.72 | 2019-2020 | |
| Exact Sciences Corporation | $27.91 | 2024-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $25.85 | 2021 | |
| Tempus Ai, INC | $23.80 | 2024 | |
| Xeris Pharmaceuticals, INC. | $21.73 | 2022 | |
| Supernus Pharmaceuticals, INC. | $21.06 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.01 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $18.58 | 2025 | Auvelity |
| Regeneron Healthcare Solutions, INC. | $16.02 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.27 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $14.93 | 2021 | |
| Sanofi Pasteur INC. | $14.72 | 2020 | |
| Medtronic Minimed, INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.